At the recent American Congress of Rheumatology in San Fransisco this week, we received fantastic news on two promising trial results.

1. AstraZeneca Phase IIb Anifrolumab 300 mg showed positive results, where it produced a response in 34.4 percent of patients after 169 days of treatment and this rose to more than 50 percent after a year….

[Anifrolumab] produced a response in 34.4 percent of patients after 169 days of treatment and this rose to more than 50 percent after a year. …On the downside, there was an increase in patients reporting both Herpes zoster, or shingles, and influenza. However, [Bing Yao, head of respiratory, inflammatory and autoimmune research at AstraZeneca’s biotech unit MedImmune] …said these conditions were readily treated with antivirals. Link to Reuters press release.

2. For the third time, Belimumab (marketed as Benlysta) has shown positive third phase trial results; this time from trials where Belimumab was administered subcutaneosly in addition to standard treatment.

We hope that this very positive news signals a true turning point in the development of new lupus treatments.

Live Facebook Feed

Comments Box SVG iconsUsed for the like, share, comment, and reaction icons
4 days ago
LUPUS EUROPE

As much as we love hearing from you all and appreciate the time you take to share how you #kicklupus and inspire others, we cannot allow any content specifically about healing products for lupus.

We would greatly appreciate if you followed this rule when posting on the page.
Thank you
... See MoreSee Less

1 week ago
LUPUS EUROPE

#WorldLupusDay finishes today, but #lupusawareness does not. There is so much more we can do to make life with #lupus better. Watch our vice chair, Anne Charlet, talk about her journey of becoming a Board Member.
You can also join us and become a volunteer
... See MoreSee Less

Comment on Facebook

Wauvvvv SO good looking :-)

LUPUS EUROPE Uniting people with Lupus throughout Europe
Send